<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

2017 Review: Precision Medicine - From Traditional to Tailored Treatment

dna sequence, precision medicine 2017 review, personalized medicine, biomarkers, companion diagnostics, liquid biopsy

dna sequence, precision medicine 2017 review, personalized medicine, biomarkers, companion diagnostics, liquid biopsyWith continued advances in technology, and the increasing focus on individualized therapy, the field of precision medicine has once again been a major focus in 2017. Following on from the launches of the Precision Medicine Initiative and the All of Us Research Program in the US in 2016, and many other initiatives around the globe in the past 2 years, this rapidly growing field has become a major research investment sector.

Technological Advances Allow Personalized Treatment Plans

Precision medicine refers to the tailoring of medical treatment to the individual characteristics of each patient, identifying which approaches will be the most effective for which patients, based on genetic, environmental, and lifestyle factors.

Personalization of therapy is not a novel concept. Blood typing, for example, has been used for decades to guide blood transfusions. However, informatics and information breakthroughs in genomics such as full-genome sequencing and next-generation sequencing (NGS) technologies, combined with other omics signatures (proteomic and metabolomics), has allowed patient stratification to make therapy personalized.

Biomarkers and Companion Diagnostics are the Key to Successful Precision Medicine

To realize precision medicine, two components are essential:

  • a targeted therapy
  • a companion test to identify a biomarker.

Companion diagnostics are used to identify the genes, proteins, and other signatures needed to implement the use of a targeted therapy. This allows the stratification of patients within a given illness – selecting only those who are likely to benefit from a therapy to then receive that targeted agent.

Therefore, biomarkers that can predict treatment response are critical for the success of precision therapy for cancer patients, and in oncology drug development. Moreover, during the course of the disease, companion diagnostics may also help provide additional information on the effectiveness of treatment or the disease progression.

2017 Brought Historic FDA Approvals to Drive Forward Precision Medicine

Innovation in this domain was highly visible during 2017. First in May, for the first time in their history, the U.S. Food and Drug Administration approved a cancer treatment based on a biomarker regardless of the origin of disease.

The agency granted an accelerated approval to Keytruda® (pembrolizumab, Merck) for the treatment of adults and children with unresectable solid tumors who have specific genetic biomarkers, known as microsatellite instability-high (MSI-H) and DNA mismatch repair (dMMR), and where tumors have progressed following prior therapy or there are no satisfactory treatment alternatives.

A couple of months later, the first NGS oncology panel test for multiple companion diagnostic indications was FDA approved, marking an important step forward in advancing precision medicine by ensuring the best pairing between patients and drugs.

Liquid Biopsies Advanced Clinical Oncology

Today, tumor biopsy is the main way physicians diagnose most types of cancer, but biopsies can also be used to make treatment decisions as illustrated before.

However, such a sampling method may be inadequate for the comprehensive characterization of a patient’s tumor, as it has been demonstrated that tumors are highly heterogeneous and that genetic diversity can also alter over time. Furthermore, depending on the location of the tumor and the patient’s general health, surgical biopsy procedures may not always be feasible.

However, with the continued development of sensitive techniques, the analysis of circulating tumor cells (CTCs) and cell-free circulating nucleic acids (in particular, circulating tumor DNA (ctDNA) and exosomes) in liquid biopsy has also been intensively investigated this year.

Liquid biopsies offer the opportunity to temporally measure tumor burden, and also the genotype and phenotype of the cancer over time, to detect early evidence of resistance or disease recurrence.

2018 – The Precision Medicine Era Continues

In the era of precision medicine, the implementation of NGS technologies, companion tests, and liquid biopsies offers a great opportunity to increase the number of therapeutic opportunities for every single patient, improving cancer patient care over the years to come.


Related Posts